European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issues positive opinion for aflibercept biosimilar YESAFILI®

News
Article

The Biocon Biologics, Ltd product moves on to review by the European Commission, with an expected decision in late September 2023.

A gloved hand fills a syringe with an injectable drug. Image credit: ©BillionPhotos.com – stock.adobe.com

The European Commission will consider the CHMP opinion and is expected to announce its decision by the end of September. Image credit: ©BillionPhotos.com – stock.adobe.com

On Monday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending approval of YESAFILI®, an aflibercept biosimilar. The opinion was announced in a news release from Biocon Biologics Ltd (BBL,) a subsidiary of Biocon Ltd.1 The European Commission will consider the CHMP opinion and is expected to announce its decision by the end of September.

YESAFILI® is described as “highly similar” to the reference product  Eylea® (aflibercept). According to Biocon Biologics, date demonstrates “that YESAFILI® has comparable quality, safety and efficacy to Eylea®.”1 The biosimilar is intended for the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO), neovascular (wet AMD) age-related macular degeneration, visual impairment due to myopic choroidal neovascularisation (myopic CNV) and visual impairment due to diabetic macular oedema (DME).

If the European Commission grants marketing authorisation, the company will publish a summary of product characteristics (SmPC) in the European public assessment report (EPAR). That document will contain more detailed recommendations and use cases.1

"This is further confirmation of our strong commitment to providing high-quality and affordable medicines and represents another significant milestone as we continue to expand our biosimilar offerings across the globe,” said Shreehas Tambe, CEO and managing director of Biocon Biologics. “We look forward to making a meaningful difference to patients in the EU impacted by macular degeneration and diabetic retinopathy through YESAFILI®."1

Reference

1. Biocon Biologics Announces Positive CHMP Opinion for YESAFILI®, Biosimilar Aflibercept. News release. July 24, 2023. https://www.prnewswire.com/news-releases/biocon-biologics-announces-positive-chmp-opinion-for-yesafili-biosimilar-aflibercept-301883594.html
Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.